Semaglutide and Menopause: Does It Work?
US$ 21.76
glp-1 news today november 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Recently interviewed by @bostonglobe regarding
Description
Back Barany, G, Barany, MJ (27 Sept 2024) 'Foundational contributions of Svetlana Mojsov to the GLP-1 field', Explorations of Drug Science , 2, 688700
Key Segment Analysis 16.2
All five treatment groups had reductions in absolute body weight and BMI at 24 weeks, but the exenatide and dapagliflozin group had greater weight loss than those receiving only dapagliflozin or dapagliflozin and metformin ( P = .005)
[106] Sandoz' 2026 offering would be for diabetes only, [107] while Biocon hopes to offer generic semaglutide for diabetes and weight loss by 2027
The ORION studies, with over 12,000 patients, showed strong LDL reduction and only mild injection-site reactions and no major ADR's
Continue your GLP-1 medication unless advised otherwise by your prescribing clinician
